News Releases

Date Title and Summary Additional Formats
Toggle Summary Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology (ACR)
View HTML
Toggle Summary Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney Health Alliance ChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL
View HTML
Toggle Summary ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate Mountain View, CA - July 24, 2007 - ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered
View HTML
Toggle Summary ChemoCentryx Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development
MOUNTAIN VIEW, Calif. , Jan. 7, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX507, the Company's novel, wholly-owned inhibitor of the chemokine receptor known as CCR9. The double-blind, placebo-controlled study will
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 into Clinical Development
Solidifies Company's Leadership Position in Targeting Chemokine Receptor CCR9 for Gastrointestinal Diseases
View HTML
Toggle Summary ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics
ChemoCentryx and Forest Laboratories to Collaborate on The Development and Commercialization of Novel Oral Rheumatoid Arthritis and Multiple Sclerosis Therapeutics March 15, 2004; San Carlos, CA and New York, NY — ChemoCentryx, Inc., a privately held focused pharmaceutical company, and Forest
View HTML
Toggle Summary ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Companies have completed the EU regulatory application   for marketing approval of avacopan Regulatory submission based on positive data from the pivotal P hase-III ADVOCATE trial of avacopan ST. GALLEN , Switzerland and MOUNTAIN VIEW, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius
View HTML
Toggle Summary ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced glucocorticoid toxicity -- -- Significantly improved kidney function compared to glucocorticoid-containing SOC
View HTML
Toggle Summary ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
MOUNTAIN VIEW, Calif. and ST GALLEN, CH , May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. , (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal
View HTML